Can I Take Melatonin with Provigil (Modafinil)?

Provigil is the brand name for modafinil, a wakefulness-promoting agent FDA-approved for excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, and shift-work disorder. Melatonin is an over-the-counter dietary supplement version of the hormone the pineal gland releases in response to darkness; it is not FDA-approved as a drug for insomnia in the United States and is regulated as a supplement, so product potency and purity are not guaranteed the way a prescription drug's are.

For most adults, taking melatonin and modafinil on the same day does not create a dangerous blood-level interaction. The two compounds are not known to compete for the same metabolic pathway in a way that would meaningfully raise or lower each other's plasma concentration at typical doses. The realistic concern is pharmacodynamic and practical: modafinil promotes arousal and melatonin promotes sleep onset, so timing the two poorly can mean they work against each other, or that melatonin taken too early blunts modafinil's benefit, or taken too late leaves you groggy the next morning. Dose separation, not avoidance, is the standard practical approach, and anyone on other CNS-active medications, or with a CYP1A2-inhibiting drug such as fluvoxamine in their regimen, should confirm the plan with a prescriber or pharmacist rather than assume it applies to them.

What is actually established

Modafinil's FDA-approved prescribing information describes an elimination half-life of roughly 15 hours in healthy adults, with metabolism occurring primarily through amide hydrolysis and secondary CYP3A4 involvement, and the drug carries no listed interaction warning for melatonin (FDA label). That long half-life is the reason a morning dose can still be measurably present at night, which is the practical driver of sleep-onset complaints in modafinil users.

Melatonin's short elimination half-life for immediate-release oral formulations, generally cited in the 20-to-60-minute range in pharmacology references, means it clears the bloodstream well before a following morning dose of modafinil in most people, which is why immediate-release rather than extended-release melatonin is the more sensible pairing when overlap with a morning stimulant matters.

No published trial has evaluated modafinil plus melatonin as a combined intervention. The safety inference here comes from each drug's independent record, not from a study of the pair together. That is an important boundary: absence of a reported interaction is not the same as a trial proving safety in combination.

What is pharmacologically plausible but not proven for this combination

Melatonin is primarily metabolized by CYP1A2, and modafinil is not a known potent CYP1A2 inhibitor or inducer at standard doses, which makes a clinically meaningful pharmacokinetic interaction between the two implausible on mechanistic grounds. This is a reasonable inference from each drug's known metabolic pathway, not a finding from a study that dosed them together, and it should be described that way rather than as a proven fact.

A shared minor pathway, CYP2C19, is used by both modafinil and melatonin to a lesser degree. Whether this produces a detectable effect in people who are poor CYP2C19 metabolizers has not been specifically studied for this combination, and any statement about how much slower clearance would be in that subgroup would be speculative without a dedicated pharmacokinetic study. If you know you are a CYP2C19 poor metabolizer, that is a reasonable detail to raise with your prescriber rather than something to self-adjust around.

Melatonin's possible effect on glucose tolerance in carriers of certain MTNR1B gene variants has been raised in the research literature as a topic of interest for late-evening melatonin dosing generally. Whether this matters for someone also taking modafinil has not been studied, and the underlying genetic and dose-response claims from the source material for this article could not be verified against a specific paper here, so no precise percentage or dose threshold should be treated as confirmed. The reasonable, conservative takeaway for someone with prediabetes or diabetes is to keep melatonin doses low and mention the combination to whoever manages their glucose control, not to rely on a specific numeric claim.

What is not established

There is no controlled evidence that melatonin reduces modafinil's effectiveness for its approved indications, and there is no controlled evidence that modafinil suppresses endogenous melatonin production. Claims about exact minutes of sleep-onset improvement, specific percentages of physicians recommending the combination, or named-author quotations attributed to specific researchers could not be traced to a verifiable source in the material available for this article and have been removed rather than repeated. If a reader has seen a precise number for melatonin's effect on sleep latency attributed to a meta-analysis, that number should be checked against the original paper before being treated as a settled fact, since prior drafts of pages like this one have carried citation errors.

Long-term safety data for nightly melatonin use beyond roughly three months in adults, and for melatonin combined with a long-term wakefulness agent, are limited. This is a genuine gap, not a reassurance.

Should you separate the doses, and by how much?

The practical approach clinicians commonly describe is straightforward even without a dedicated interaction trial to anchor it: take modafinil early in the day, consistent with its labeled dosing (a single morning dose for narcolepsy or OSA, or roughly an hour before a shift for shift-work disorder), and take melatonin, if you and your prescriber decide it is appropriate, in the 30 to 60 minutes before your intended sleep time. Because modafinil's half-life is long, taking it as early in the day as your schedule allows gives the best chance that its plasma level has meaningfully declined by bedtime, independent of whether melatonin is added.

Starting at a low melatonin dose (commonly discussed as 0.5 to 1 mg) rather than the 5 or 10 mg doses sold in many over-the-counter products is a reasonable starting point, since higher doses have not been shown to add proportional benefit for sleep onset in the general insomnia literature and may increase next-day grogginess. This is a general dosing principle from melatonin research broadly, not a number specific to modafinil users, and it is not a substitute for an individualized recommendation from a prescriber.

When this combination needs closer supervision or should be avoided

• Fluvoxamine or other CYP1A2 inhibitors. Fluvoxamine is a well-established potent inhibitor of CYP1A2 and can substantially raise melatonin blood levels. Anyone taking fluvoxamine (or another strong CYP1A2 inhibitor) alongside modafinil should not add melatonin without direct clinician guidance, since the combination could produce more sedation than intended and blunt the reason for taking modafinil in the first place.
• Autoimmune disease or immunosuppressive therapy. Melatonin has documented immunomodulatory activity in laboratory research. Organ transplant recipients and people on immunosuppressive regimens should not add melatonin without checking with the specialist managing that therapy.
• Children and adolescents. Modafinil is not FDA-approved for pediatric use, and melatonin's long-term pediatric safety data are limited. Combining an off-label stimulant with a supplement in a child adds a second unmonitored variable and should go through a pediatric sleep specialist rather than self-directed use.
• Prediabetes or diabetes. Given the unresolved glucose-tolerance question above, monitoring fasting glucose after starting melatonin is a reasonable precaution rather than an established requirement.
• Extended-release or high-dose melatonin products. These stay in the system longer and are more likely to overlap with a morning modafinil dose than an immediate-release, low-dose product.

When to seek urgent care rather than adjust the regimen yourself

New chest pain, fainting, severe agitation, hallucinations, or a rash after starting either drug warrants urgent medical evaluation rather than a wait-and-see approach at home. Modafinil has a rare but recognized association with serious skin reactions in its FDA labeling; any new rash after starting or changing modafinil dosing should be reported to a prescriber promptly rather than managed by adjusting melatonin timing.

Evidence-status interaction assessment: modafinil plus melatonin

What to do if you are already taking both

If you have been taking melatonin and modafinil together without problems, that is not itself concerning, but it is worth confirming three things with your prescriber at your next visit: that you are separating the two by a meaningful window (commonly discussed as roughly 12 hours), that you are using the lowest melatonin dose that works for you, and that you are not on a medication such as fluvoxamine that changes the picture. If modafinil seems less effective since adding melatonin, the most likely explanation is timing overlap or an extended-release melatonin product persisting into the morning, and both are worth raising before assuming the drugs are fundamentally incompatible.

Reported figures vary between studies and have not been independently confirmed here, so claims are described in general terms where specific data could not be verified. This article should be reviewed by a qualified clinician before clinical use.